HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium.

Abstract
Doxorubicin cardiotoxicity is a multifactorial process in which the alcohol metabolite doxorubicinol mediates the transition from reversible to irreversible damage. We investigated whether the tubulin-active taxane paclitaxel increases conversion of doxorubicin to doxorubicinol, thus explaining the high incidence of congestive heart failure when doxorubicin is used with paclitaxel. Specimens of human myocardium from patients undergoing bypass surgery were processed to obtain cytosolic fractions in which doxorubicin was converted to doxorubicinol by NADPH-dependent aldo/keto or carbonyl reductases. In this model, clinically relevant concentrations of paclitaxel (1-2.5 microM) increased doxorubicinol formation by mechanisms consistent with allosteric modulation of the reductases. Stimulation was observed over a broad range of basal enzymatic activity, and was accompanied by a similar pattern of enhanced formation of doxorubicinol aglycone, a metabolite potentially involved in the reversible phase of cardiotoxicity. The closely related analogue docetaxel had effects similar to paclitaxel, but increased doxorubicinol formation over a narrower range of enzymatic activity. The unrelated tubulin-active alkaloid vinorelbine had no effect. These results demonstrate that taxanes have a unique potential for enhancing doxorubicin metabolism to toxic species in human myocardium. The effects on doxorubicinol formation provide clues to explain the clinical pattern of doxorubicin-paclitaxel cardiotoxicity and also caution against the potential toxicity of combining docetaxel with high cumulative doses of doxorubicin.
AuthorsG Minotti, A Saponiero, S Licata, P Menna, A M Calafiore, G Teodori, L Gianni
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 7 Issue 6 Pg. 1511-5 (Jun 2001) ISSN: 1078-0432 [Print] United States
PMID11410484 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Bridged-Ring Compounds
  • Taxoids
  • Tubulin
  • Docetaxel
  • taxane
  • Vinblastine
  • Doxorubicin
  • Paclitaxel
  • Vinorelbine
Topics
  • Antineoplastic Agents (pharmacology)
  • Antineoplastic Agents, Phytogenic (pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bridged-Ring Compounds (pharmacology)
  • Docetaxel
  • Dose-Response Relationship, Drug
  • Doxorubicin (administration & dosage, metabolism)
  • Drug Synergism
  • Heart (drug effects)
  • Humans
  • Myocardium (metabolism)
  • Paclitaxel (administration & dosage, analogs & derivatives)
  • Taxoids
  • Tubulin (metabolism)
  • Vinblastine (analogs & derivatives, pharmacology)
  • Vinorelbine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: